Loading
Life sciences · Journal article
Acs Applied Materials & Interfaces · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The immunosuppressive tumor microenvironment, along with the vascular barrier within B16F10 melanoma, frequently compromises the therapeutic outcomes of antitumor immunotherapy. Hydrogels, possessing three-dimensional network structures, provide a platform for localized drug delivery. Herein, we reported a thermoresponsive polypeptide hydrogel co-loaded with mitoxantrone (MTX) and the angiogenesis inhibitor nintedanib (NE), combined with immune checkpoint blockade therapy, to address these challenges. Results demonstrated that the release of MTX induced immunogenic cell death of tumor cells and released tumor-associated antigens, while the release of NE inhibited angiogenesis, promoted drug permeation and immune cell infiltration, enhanced therapeutic efficacy, and suppressed tumor proliferation and metastasis. In a melanoma-bearing mouse model, the combination of intratumoral injection of MTX/NE-loaded hydrogel with intravenous injection of anti-PD-1 elicited a strong systemic anti-tumor immune response, successfully inhibiting tumor growth and metastasis, while prolonging animal survival. Overall, this study established a hydrogel drug delivery strategy to overcome B16F10 melanoma, demonstrating strong potential in clinical cancer therapy.